Skip to main content
Premium Trial:

Request an Annual Quote

Curiox Biosystems: Don O'Neil

Curiox Biosystems, a Woburn, Massachusetts-based life sciences sample prep company, has appointed Don O'Neil as chief commercialization officer. O'Neil has more than 25 years of sales and marketing experience in life science research, pharmaceuticals, sequencing, and diagnostics, including stints with Illumina, Invitrogen, and Millipore. He has also previously served as senior VP of sales and strategic partnerships at Orflo, and chief commercial officer of Gemini Biosystems. He holds an MS in mechanical engineering from the University of California, San Diego and an MBA from Cornell University.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.